J. Chesney

Matthew D. Hellmann, Joseph D. Szustakowski, Hossein Borghaei, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

G. Linette, C. Horak, J. Wolchok, 2016, The Lancet. Oncology.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

D. Schadendorf, G. Linette, J. Wolchok, 2010, The Lancet. Oncology.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

D. Jackson, A. Giobbie-Hurder, C. Horak, 2018, Science Translational Medicine.

High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.

L. Leng, R. Bucala, C. Metz, 2002, Cancer research.

An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.

R. Bucala, C. Metz, R. Mitchell, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and Then Ras Proteins Are Required for Tumor Initiation and Progression*

D. Dean, A. Postigo, Yongqing Liu, 2013, The Journal of Biological Chemistry.

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer

J. Chesney, S. Telang, J. O’Neal, 2016, Breast Cancer Research and Treatment.

Role of PFKFB3-Driven Glycolysis in Vessel Sprouting

P. Carmeliet, R. Deberardinis, J. Hofkens, 2013, Cell.

Molecular Pathways: Regulation of Metabolism by RB

J. Chesney, B. Clem, Brian F. Clem, 2012, Clinical Cancer Research.

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

J. Larkin, J. Kirkwood, H. Kluger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.

P. Carmeliet, M. Cascante, H. Gerhardt, 2014, Cell metabolism.

Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

K. Harrington, L. Siu, D. Rischin, 2021 .

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis

J. Chesney, 2006, Current opinion in clinical nutrition and metabolic care.

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

J. Kirkwood, Kevin B. Kim, M. Shi, 2011, Clinical Cancer Research.

Disruption of Inducible 6-Phosphofructo-2-kinase Ameliorates Diet-induced Adiposity but Exacerbates Systemic Insulin Resistance and Adipose Tissue Inflammatory Response*

Y. E. Chen, Huan Wang, R. Chapkin, 2009, The Journal of Biological Chemistry.

Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling

A. Lane, A. Yalçin, J. Eaton, 2010, Oncogene.

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

A. Khurana, Song Zhang, V. Shridhar, 2018, International journal of cancer.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Novel Small Molecule Antagonist of Choline Kinase-α That Simultaneously Suppresses MAPK and PI3K/AKT Signaling

A. Yalçin, J. Trent, J. Chesney, 2011, Oncogene.

Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

G. Linette, C. Horak, J. Wolchok, 2015 .

Myeloid‐derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy

K. Yaddanapudi, R. Mitchell, J. Chesney, 2017, Journal of leukocyte biology.

Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma

Donald M Miller, N. Natarajan, J. Chesney, 2011, Drugs.

Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype.

M. Ratajczak, D. Dean, S. El-Naggar, 2009, Cell stem cell.

Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma

S. Rai, M. Egger, J. Chesney, 2021, Molecular Diagnosis & Therapy.

Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model.

J. Eaton, J. Chesney, S. Telang, 2007, Neoplasia.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

A. Hauschild, I. Puzanov, C. Garbe, 2019, British Journal of Cancer.

Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor

J. Trent, J. Chesney, S. Telang, 2015, Oncotarget.

Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth

A. Yalçin, J. Eaton, J. Chesney, 2012, Molecular Cancer.

The oncoprotein H-RasV12 increases mitochondrial metabolism

A. Lane, J. Chesney, S. Telang, 2007, Molecular Cancer.

Ras transformation requires metabolic control by 6-phosphofructo-2-kinase

A. Lane, A. Yalçin, J. Eaton, 2006, Oncogene.

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

J. Chesney, Y. Imbert-Fernandez, Susan M. Dougherty, 2021, Cells.

A role for peripheral blood fibrocytes in Lyme disease?

R. Bucala, J. Chesney, H. Lanners, 2002, Medical hypotheses.

422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

K. Harrington, A. Pavlick, T. Bowles, 2020 .

Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.

N. Hanna, S. Jalal, A. Ganti, 2022, Journal of Clinical Oncology.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

5‐(3,3‐Dimethyle‐1‐Triazeno) Imidazole‐4‐Carboxamide and Interleukin‐2 Adjuvant Therapy in Resected High‐Risk Primary and Regionally Metastatic Melanoma

S. Rai, Donald M Miller, Jianmin Pan, 2019, The American journal of the medical sciences.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

A. Abernethy, A. Ribas, R. Gonzalez, 2012, Journal of Translational Medicine.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

D. Schadendorf, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

J. Chesney, S. Telang, Smita Ranjan, 2018, Melanoma research.

Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.

S. Woo, J. Chesney, E. Burton, 2017, World neurosurgery.

Thermal liquid biopsy for monitoring melanoma patients under surveillance during treatment: A pilot study.

O. Abián, A. Velázquez‐Campoy, Á. Lanas, 2018, Biochimica et biophysica acta. General subjects.

Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology/RTOG 0631

P. Gerszten, P. Iyengar, R. Timmerman, 2019, International Journal of Radiation Oncology*Biology*Physics.

Transient T-cell depletion causes regression of melanoma metastases

Dianne Miller, K. McMasters, J. Chesney, 2008 .

Transient T cell depletion causes regression of melanoma metastases

K. McMasters, Donald M Miller, J. Chesney, 2008, Journal of Translational Medicine.

Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC).

M. Ross, J. Nemunaitis, K. Delman, 2015 .

Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

G. Linette, J. Wolchok, F. Hodi, 2016 .

A phase II trial of biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, interferon, and digoxin in melanoma matients

Dianne Miller, J. Chesney, D. Laber, 2007 .

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

J. Larkin, J. Kirkwood, H. Kluger, 2019, Journal of Clinical Oncology.

The Rb/E2F pathway and Ras activation regulate RecQ helicase gene expression.

D. Dean, S. El-Naggar, Yongqing Liu, 2008, The Biochemical journal.

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

J. Nemunaitis, John W Walker, Cheng-Pang Hsu, 2019, EBioMedicine.

The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs.

M. Ross, I. Puzanov, J. Chesney, 2019, JAMA dermatology.

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

M. Ross, I. Puzanov, M. Milhem, 2016 .

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

G. Linette, J. Nemunaitis, L. Hutchins, 2018, Melanoma research.

Digitalis, A Targeted Therapy for Cancer?

Donald M Miller, J. Chesney, D. Laber, 2009, The American journal of the medical sciences.

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth

John O Trent, A. Lane, A. Yalçin, 2008, Molecular Cancer Therapeutics.

Glucose Availability and Glycolytic Metabolism Dictate Glycosphingolipid Levels

J. Rathmell, Leah J. Siskind, L. Beverly, 2015, Journal of cellular biochemistry.

Melanoma of unknown primary: favorable survival persists in the immunotherapy era

J. Chesney, S. Maharaj, Donald Miller, 2022, International journal of dermatology.

Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer

J. Trent, Donald M Miller, J. Chesney, 2013, Molecular Cancer Therapeutics.

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2020 .

Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis

D. Dean, A. Postigo, Yongqing Liu, 2014, Nature Communications.

Block Copolymer Micelles for Controlled Delivery of Glycolytic Enzyme Inhibitors

Y. Bae, J. Chesney, B. Clem, 2011, Pharmaceutical Research.

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation

R. Bucala, J. Trent, J. Chesney, 2012, Journal of Translational Medicine.

Venous and arterial thromboembolism with immunotherapy compared to platinum-based therapy.

A. Rojan, G. Kloecker, J. Chesney, 2022, Thrombosis Research.

Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non–small cell lung cancer cell survival

J. Chesney, S. Telang, Y. Imbert-Fernandez, 2019, The Journal of Biological Chemistry.

Abstract 4478: 6-Phosphofructo-2-Kinase (PFKFB3): At the crossroads of resistance to targeted cancer therapies

J. Trent, J. Chesney, S. Telang, 2015 .

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib

J. Chesney, S. Telang, J. O’Neal, 2014, Cancer & Metabolism.

Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials

J. Malvehy, H. Gogas, R. Gutzmer, 2018, Annals of Oncology.

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Sara W. Bird, Erinna F. Lee, Michael D. Kim, 2016 .

lipase activity Effect of diet on fat cell size and hormone-sensitive

Y. E. Chen, Jifeng Zhang, R. Barnard, 2015 .

Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality.

A. Yalçin, R. Bucala, J. Chesney, 2005, Biochemical and biophysical research communications.

3:36 PM Abstract No. 375 Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors

S. Raman, E. Chan, A. Prat, 2018 .

Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652

Lee, Duchen, Izzo, 2016 .

Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

M. Lotze, H. Kluger, B. Curti, 2017 .

Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy

H. Donninger, K. Yaddanapudi, Chi Li, 2023, Science advances.

Rb1 family mutation is sufficient for sarcoma initiation

D. Dean, A. Postigo, Yongqing Liu, 2013, Nature Communications.

Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients

N. Garbett, G. Brock, J. Chesney, 2023, Current oncology.

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

K. Harrington, N. Senzer, K. Delman, 2014, Journal of Immunotherapy for Cancer.

Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients

K. Yaddanapudi, J. Grewal, D. Mahalingam, 2016 .

Abstract CT206: PFK-158, first-in-man and first-in-class inhibitor of PFKFB3/ glycolysis: A phase I, dose escalation, multi-center study in patients with advanced solid malignancies

P. Pohlmann, J. Chesney, G. Tapolsky, 2015 .

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.

J. Nieva, S. Gettinger, J. Lutzky, 2019, Journal of Clinical Oncology.

The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts

J. Chesney, S. Telang, Y. Imbert-Fernandez, 2014, Cancer & Metabolism.

Block Copolymer Micelles for Controlled Delivery of Glycolytic Enzyme Inhibitors

Y. Bae, J. Chesney, B. Clem, 2012, Pharmaceutical Research.

PFKFB2 regulates glycolysis and proliferation in pancreatic cancer cells

A. Yalçin, A. Iglesias, J. Chesney, 2020, Molecular and Cellular Biochemistry.

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017 .

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

A. Hauschild, C. Garbe, P. Friedlander, 2023, Journal for ImmunoTherapy of Cancer.

Obtaining Routine Blood Cultures During Interleukin-2-Containing Therapy Is Unnecessary

F. Arnold, G. Kloecker, J. Chesney, 2009, American journal of clinical oncology.

Fructose-2,6-bisphosphate links glucose to survival and growth

A. Yalçin, J. Chesney, S. Telang, 2014, Cancer & Metabolism.

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.

D. Schadendorf, J. Hou, M. Middleton, 2023, Journal of Clinical Oncology.

Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.

J. Hecht, A. Prat, J. Chesney, 2018 .

Society for Melanoma Research 2015 Congress

Harrington, M., T., 2015 .

Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy

G. Kloecker, J. Chesney, Vatsala Katiyar, 2023, Cancers.

883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

P. Hari, T. Wise-Draper, A. Sarnaik, 2022, Annals of Oncology.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

G. Linette, M. Ross, K. Harrington, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

J. Kirkwood, Kevin B. Kim, M. Shi, 2011, Clinical Cancer Research.

Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.

A. Yalçin, J. Chesney, S. Telang, 2009, Experimental and molecular pathology.

Role of PFKFB3-Driven Glycolysis in Vessel Sprouting

P. Carmeliet, R. Deberardinis, J. Hofkens, 2013, Cell.

Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2).

R. Bucala, D. Hoelzer, J. Chesney, 2003, International Journal of Oncology.

Bacterial glutathione: a sacrificial defense against chlorine compounds

J. Eaton, J. Mahoney, J. Chesney, 1996, Journal of bacteriology.

Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)

G. Linette, C. Horak, J. Wolchok, 2016 .